Chris Seagle is the Vice President, Head of Portfolio Strategy at Coherus Biosciences leading activities related to launch readiness and post-launch commercialization for biosimilars and novel therapeutics. In this role, he also works as part of the business development and licensing (BD&L) team. His background in market access and pricing for US and global pharmaceuticals is foundational to creating broadest patient access and commercialization speed. Prior to Coherus, Chris has held market access and commercial leadership roles with PTC Therapeutics, AbbVie, EMD Serono, and Sanofi. He completed his PhD in Biomedical Engineering and an MBA both at the University of North Carolina at Chapel Hill.